New York (Reuters Health)
GAITHERSBURG, Md., Feb 22 (Reuters) – A U.S. advisory
panel voted in favor of recommending approval for Corin Group Plc’s (CRG.L:Research hip resurfacing device on Thursday.
The Food and Drug Administration will make the final decision on whether to allow sales of the Cormet device. The agency usually follows panel recommendations.
…In a 4-1 vote, the FDA’s panel of outside experts supported the device but said the agency should require a follow-up study after approval to evaluate long-term performance…
Read Complete Article at Reuters